Developing new treatment strategies for patients with incurable diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effectiveness of a multidisciplinary group known as the Evolutionary Tumor Board (ETB) in creating therapeutic strategies for patients who have no curative options available. The ETB will assess individual patient cases and recommend tailored treatment approaches based on their unique circumstances. Participants must have a life expectancy of more than three months and be willing to consider the ETB's recommendations while allowing for ongoing clinical data collection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
* Participant must have a life expectancy greater than 3 months
* Participant must have an ECOG performance status 0-2
* Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
* Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.

Exclusion Criteria:

* None

Where it's running

• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting

Study contacts

• Principal investigator: Jingsong Zhang, MD — Moffitt Cancer Center
• Study coordinator: Sara Donadelli
• Email: Sara.Donadelli@moffitt.org
• Phone: 813-745-8111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Impact of exercise and diet on quality of life for patients with incurable esophageal and stomach cancer

  This study is testing if a program that combines exercise and better nutrition can improve the quality of life for patients with incurable esophageal and stomach cancer after their first treatment hasn't worked.

  Recruiting at 18 sites Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland and 21 other locations · NCT06138223

• Melanoma treatment with immunotherapy guided by serial ctDNA testing

  This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07930182

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

• Dendritic Cell Vaccine with HER2-targeted Therapy or Nivolumab for Breast Cancer with Leptomeningeal Metastasis

  This trial tests a dendritic cell vaccine added to trastuzumab for Her2-positive disease or to nivolumab for Her2-negative disease to see if it can be given safely to people with breast cancer that has spread to the leptomeninges.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07694986

• See if SAVI Scout MD helps surgeons localize breast cancer more precisely

  This study tests whether the SAVI Scout MD radar reflectors help surgeons find and remove breast cancer more accurately, potentially reducing the need for a second operation.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07686250

• PIPAC with Mitomycin C for unresectable peritoneal cancer

  This phase 1 study tests a breathy, pressurized chemotherapy method (PIPAC-MMC) to see if it is safe and tolerable for adults with unresectable peritoneal carcinomatosis from colorectal, appendiceal, or small bowel cancers.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07487168

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.